$23.07
5.46% today
Nasdaq, Apr 01, 06:47 pm CET
ISIN
US03753U1060
Symbol
APLS

Apellis Pharmaceuticals, Inc. Stock price

$21.87
-3.28 13.04% 1M
-6.97 24.17% 6M
-10.04 31.46% YTD
-37.84 63.37% 1Y
-28.94 56.96% 3Y
-4.92 18.37% 5Y
+7.84 55.88% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-2.40 9.89%
ISIN
US03753U1060
Symbol
APLS
Sector

Key metrics

Market capitalization $2.75b
Enterprise Value $2.80b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.59
P/S ratio (TTM) P/S ratio 3.51
P/B ratio (TTM) P/B ratio 11.91
Revenue growth (TTM) Revenue growth 97.02%
Revenue (TTM) Revenue $781.37m
EBIT (operating result TTM) EBIT $-164.98m
Free Cash Flow (TTM) Free Cash Flow $-88.27m
Cash position $412.61m
EPS (TTM) EPS $-1.60
P/E forward negative
P/S forward 3.17
EV/Sales forward 3.24
Short interest 21.00%
Show more

Is Apellis Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Apellis Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Apellis Pharmaceuticals, Inc. forecast:

15x Buy
65%
8x Hold
35%

Analyst Opinions

23 Analysts have issued a Apellis Pharmaceuticals, Inc. forecast:

Buy
65%
Hold
35%

Financial data from Apellis Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
781 781
97% 97%
100%
- Direct Costs 119 119
104% 104%
15%
662 662
96% 96%
85%
- Selling and Administrative Expenses 498 498
0% 0%
64%
- Research and Development Expense 328 328
8% 8%
42%
-163 -163
68% 68%
-21%
- Depreciation and Amortization 1.80 1.80
6% 6%
0%
EBIT (Operating Income) EBIT -165 -165
68% 68%
-21%
Net Profit -198 -198
63% 63%
-25%

In millions USD.

Don't miss a Thing! We will send you all news about Apellis Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Apellis Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
about 7 hours ago
PDUFA target action date is July 28, 2025 WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation of the supplemental New Drug Application (sNDA) for EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membrano...
Positive
Seeking Alpha
27 days ago
Commerical stage Apellis Pharmaceuticals, Inc. recently reported Q4 results that beat expectations. The company posted impressive revenue growth and cost reduction in FY2024. It is a bit of a complicated tale around this mid-cap, but the company looks set to move to profitability with the funding it has on hand.
Neutral
Seeking Alpha
about one month ago
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ET Company Participants Cedric Francois - Co-Founder and CEO Caroline Baumal - Chief Medical Officer David Acheson - EVP, Commercial Tim Sullivan - CFO Meredith Kaya - SVP, IR and Strategic Finance Conference Call Participants Jon Miller - Evercore ISI Tazeen Ahmad - Bank of America Securitie...
More Apellis Pharmaceuticals, Inc. News

Company Profile

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Head office United States
CEO Cedric Francois
Employees 710
Founded 2009
Website www.apellis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today